Results 171 to 180 of about 163,730 (308)

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

The research progress of gastric cancer vaccines: a narrative review. [PDF]

Transl Cancer Res
Wu H, Zhang F, Shao Q, Huang Z.
europepmc   +1 more source

Human cancer vaccines

Advanced Drug Delivery Reviews, 2006
Man, Stephen, Tabi, Zsuzsanna
openaire   +2 more sources

Editorial: Advances in therapeutic cancer vaccines-mechanisms and development. [PDF]

Front Immunol
George MM, Brennick CA, Moon JJ, Lihm J, Choi H.   +4 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Therapeutic cancer vaccines: navigating clinical translation and multimodal synergy. [PDF]

Front Immunol
Chu TH, Huynh TL, Phuong LT.
europepmc   +1 more source

Increasing the reporting of adverse drug reaction‐related hospitalizations using an ICD‐10‐based identification workflow: A multicentre study from Switzerland

British Journal of Clinical Pharmacology, EarlyView.
Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber, Sophie‐Charlotte Bartel, Michael Boch, Christoph Rosen, Michael Bodmer, Balthasar Luzius Hug, Thomas Stammschulte, Patrick E. Beeler   +7 more
wiley   +1 more source

Cancer vaccines and RNA therapeutics: exploring the impact of microRNAs. [PDF]

NPJ Vaccines
Rojas-Rojas MV, Muiños-García A, Arriaga-Canon C, Herrera LA.   +3 more
europepmc   +1 more source

Innovative Cancer Immunotherapy with MAGE-A3 mRNA Cancer Vaccines

Cancer causes over 10 million deaths annually worldwide and remains a significant global health challenge. This study investigated advanced immunotherapy strategies, focusing on mRNA vaccines that target tumor-specific antigens to activate the immune ...
Yong Serk Park, Hyorim Jeong, Ji Won Lee, Jin Ee Baek, Kangchan Choi, Do Hyun Lee, Ju-Eun Hong   +6 more
core   +1 more source

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source